Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Neven

Showing results (121-130 of 140) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesisA Lintermans, B Van Calster, M Van Hoydonck, et al.
Breast Cancer Research and Treatment|January 11, 2007
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of ageT Van Mieghem, K Leunen, N Pochet, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trialH S Rugo, V Diéras, K A Gelmon, et al.
Breast Cancer Research and Treatment|September 16, 2015
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effectsV O Dezentjé, F L Opdam, H Gelderblom, et al.
Breast Cancer Research and Treatment|December 14, 2017
Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsyS N Han, F Amant, E H Cardonick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 2012
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up dataA Lintermans, A Laenen, B Van Calster, et al.
Breast Cancer Research and Treatment|July 15, 2009
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen usersA S Dieudonné, D Lambrechts, B Claes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†M Piccart, G N Hortobagyi, M Campone, et al.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
Pageof 14

Showing results (121-130 of 140) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2011
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesisA Lintermans, B Van Calster, M Van Hoydonck, et al.
Breast Cancer Research and Treatment|January 11, 2007
Body mass index and HER-2 overexpression in breast cancer patients over 50 years of ageT Van Mieghem, K Leunen, N Pochet, et al.
Breast Cancer Research and Treatment|December 6, 2013
Symptoms of endocrine treatment and outcome in the BIG 1-98 studyJ Huober, B F Cole, M Rabaglio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2018
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trialH S Rugo, V Diéras, K A Gelmon, et al.
Breast Cancer Research and Treatment|September 16, 2015
CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effectsV O Dezentjé, F L Opdam, H Gelderblom, et al.
Breast Cancer Research and Treatment|December 14, 2017
Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsyS N Han, F Amant, E H Cardonick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 2012
Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up dataA Lintermans, A Laenen, B Van Calster, et al.
Breast Cancer Research and Treatment|July 15, 2009
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen usersA S Dieudonné, D Lambrechts, B Claes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†M Piccart, G N Hortobagyi, M Campone, et al.
Breast Cancer Research : BCR|August 31, 2023
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrantP Neven, P A Fasching, S Chia, et al.
Pageof 14